Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit [Yahoo! Finance]
Clearside Biomedical, Inc. (CLSD)
Last clearside biomedical, inc. earnings: 3/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.clearsidebio.com/investor-overview
Company Research
Source: Yahoo! Finance
- Unique Ability to Re-Dose CLS-AX vs Rescue Supports Regulatory & Commercial Strategy - ALPHARETTA, Ga., March 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that presentations on the Company's lead clinical program, CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD), and its suprachoroidal delivery platform were delivered at the 2025 Wet AMD & Diabetic Eye Disease Summit, a scientific meeting for industry leaders, research innovators, and clinical experts dedicated to transforming the landscape of retinal vascular disease treatments. “As the leader in suprachoroidal delivery, we valued the opportunity to participate in this industry dialogue on recent advancements and emerging therapies to improve treatment options for wet AMD
Show less
Read more
Impact Snapshot
Event Time:
CLSD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLSD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLSD alerts
High impacting Clearside Biomedical, Inc. news events
Weekly update
A roundup of the hottest topics
CLSD
News
- Clearside Biomedical (NASDAQ:CLSD) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
- Clearside Biomedical (NASDAQ:CLSD) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e+)" rating on the stock.MarketBeat
CLSD
Earnings
- 5/14/25 - Beat
CLSD
Sec Filings
- 11/25/25 - Form 8-K
- 11/14/25 - Form 10-Q
- 10/7/25 - Form 8-K
- CLSD's page on the SEC website